HematoCare: Feasibility of a Survivorship Care Plan for Hematologic Cancer Patients Undergoing HSCT

ConditionsHematologic Neoplasm Hematopoietic Stem Cell Transplantation Survivorship Cancer Survivorship

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorAzienda USL Reggio Emilia - IRCCS

About this trial

This is a feasibility study to implement a Survivorship Care (SC) Plan for patients with hematologic cancer undergoing hematopoietic stem cell transplantation (HSCT). The study evaluates if the intervention is feasible within the Italian national health system, focusing on retention rates, quality of life, unmet needs and caregiver burden

Eligibility criteria

Qualifiers

Patients with hematologic cancer candidates for HSCT (autologous or allogeneic) and their informal caregivers

Able to provide informed consent

Able to communicate in Italian

Disqualifiers

Patients or caregivers with comorbidities hindering participation (e.g., significant cognitive limitations)

Trial design

Treatments tested in this trial

Survivorship Care (SC) Plan

Treatment groups

40 Participants

are divided into 1 treatment group

Locations

Research and EBP Unit, Azienda USL-IRCCS di Reggio Emilia Reggio Emilia Italy

Sponsors and collaborators

Azienda USL Reggio Emilia - IRCCS

Lead sponsor

Source ClinicalTrials.gov